Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial

The Lancet Infectious Diseases

Volumn 19, Issue 1, 2019, Pages 35-45

  Jault, Patrick ^a   Leclerc, Thomas ^b   Jennes, Serge ^c   Pirnay, Jean Paul ^c   Que, Yok Ai ^d   Resch, Gregory ^e   Rousseau, Anne Françoise ^f   Ravat, François ^g   Carsin, Hervé ^h   Le Floch, Ronan ⁱ   Schaal, Jean Vivien ^b   Soler, Charles ^b   Fevre, Cindy ^j   Arnaud, Isabelle ^k   Bretaudeau, Laurent ^k   Gabard, Jérôme ^j  

^a Clinique de la Muette   (France)

^b PERCY MILITARY HOSPITAL   (France)

^c QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

^h CHR de Metz Thionville   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j Pherecydes Pharma   (France)

^k CleanCells   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SULFADIAZINE SILVER; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL LOAD; BURN DRESSING; BURN INFECTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EMULSION; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; INTENTION TO TREAT ANALYSIS; MULTICENTER STUDY; NONHUMAN; PATIENT CARE; PATIENT SAFETY; PHAGE THERAPY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; TOPICAL TREATMENT; ADULT; AGED; BELGIUM; BURN; CLINICAL TRIAL; DRUG TOLERANCE; FEMALE; FRANCE; MALE; MICROBIOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROCEDURES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGE; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BELGIUM; BURNS; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; TREATMENT OUTCOME;

EID: 85058276087     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30482-1     Document Type: Article

References (24)

1. d'Herelle, F, Smith, GH, The bacteriophage: its rôle in immunity. English edition, 1922, Williams & Wilkins Company, Baltimore, MA http://archive.org/details/cu31924003218991. (Accessed 17 March 2018)
2. Schooley, RT, Biswas, B, Gill, JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61 (2017), e00954–e001017.
3. Jennes, S, Merabishvili, M, Soentjens, P, et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report. Crit Care, 21, 2017, 129.
4. Kutter, E, De Vos, D, Gvasalia, G, et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11 (2010), 69–86.
5. Sulakvelidze, A, Alavidze, Z, Morris, JG Jr, Bacteriophage therapy. Antimicrob Agents Chemother 45 (2001), 649–659.
6. Viertel, TM, Ritter, K, Horz, H-P, Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother 69 (2014), 2326–2336.
7. WHO. One health. September, 2017, World Health Oragnization, Geneva http://www.who.int/features/qa/one-health/en/. (Accessed 3 July 2018)
8. Norbury, W, Herndon, DN, Tanksley, J, Jeschke, MG, Finnerty, CC, Infection in burns. Surg Infect (Larchmt) 17 (2016), 250–255.
9. Ravat, F, Le-Floch, R, Vinsonneau, C, et al. Antibiotics and the burn patient. Burns 37 (2011), 16–26.
10. Norman, G, Christie, J, Liu, Z, et al. Antiseptics for burns. Cochrane Database Syst Rev, 7, 2017 CD011821.
11. Storm-Versloot, MN, Vos, CG, Ubbink, DT, Vermeulen, H, Topical silver for preventing wound infection. Cochrane Database Syst Rev, 3, 2010 CD006478.
12. Cornaglia, G, Courcol, R, Herrmann, J-L, Kahlmeter, G, European manual of clinical microbiology. 1st edn., 2012, European Society for Clinical Microbiology and Infectious Diseases, Société Française de Microbiologie, Basel.
13. Medical Dictionary for Regulatory Activities. MedDRA term selection: points to consider. Release 4.9. MedDRA. https://www.meddra.org/sites/default/files/guidance/file/9491-1800_termselptc_r4_9_mar2015.pdf, March 2015. (Accessed 25 September 2018)
14. Gomez, R, Murray, CK, Hospenthal, DR, et al. Causes of mortality by autopsy findings of combat casualties and civilian patients admitted to a burn unit. J Am Coll Surg 208 (2009), 348–354.
15. Krishnan, P, Frew, Q, Green, A, Martin, R, Dziewulski, P, Cause of death and correlation with autopsy findings in burns patients. Burns 39 (2013), 583–588.
16. Wearn, C, Hardwicke, J, Kitsios, A, Siddons, V, Nightingale, P, Moiemen, N, Outcomes of burns in the elderly: revised estimates from the Birmingham Burn Centre. Burns 41 (2015), 1161–1168.
17. Chan, BK, Abedon, ST, Loc-Carrillo, C, Phage cocktails and the future of phage therapy. Future Microbiol 8 (2013), 769–783.
18. Nguyen, S, Baker, K, Padman, BS, et al. Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers. MBio 8 (2017), e01874–e01917.
19. Van Belleghem, JD, Clement, F, Merabishvili, M, Lavigne, R, Vaneechoutte, M, Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci Rep, 7, 2017, 8004.
20. Górski, A, Międzybrodzki, R, Borysowski, J, et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 83 (2012), 41–71.
21. Górski, A, Jończyk-Matysiak, E, Łusiak-Szelachowska, M, Międzybrodzki, R, Weber-Dąbrowska, B, Borysowski, J, The potential of phage therapy in sepsis. Front Immunol, 8, 2017, 1783.
22. Debarbieux, L, Pirnay, JP, Verbeken, G, et al. A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett, 363, 2016, fnv225.
23. Verbeken, G, De Vos, D, Vaneechoutte, M, Merabishvili, M, Zizi, M, Pirnay, JP, European regulatory conundrum of phage therapy. Future Microbiol 2 (2007), 485–491.
24. Verbeken, G, Huys, I, Ceulemans, C, Jennes, S, De Vos, D, Pirnay, JP, Bacteriophage therapy: fast-forward to the past lessons identified from the advanced therapy regulation. Burns 42 (2016), 11–12.